Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H25N3S.2C4H4O4 |
| Molecular Weight | 571.642 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.CN1CCN(CCCN2C3=C(SC4=C2C=CC=C4)C=CC=C3)CC1
InChI
InChIKey=PQDKNYWKLCFCJU-SPIKMXEPSA-N
InChI=1S/C20H25N3S.2C4H4O4/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23;2*5-3(6)1-2-4(7)8/h2-5,7-10H,6,11-16H2,1H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-
| Molecular Formula | C20H25N3S |
| Molecular Weight | 339.498 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/12523495 and http://www.genome.jp/dbget-bin/www_bget?D01412
Curator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/12523495 and http://www.genome.jp/dbget-bin/www_bget?D01412
Perazine (Taxilan) is a moderate-potency typical antipsychotic of the phenothiazine class. Perazine is an older antipsychotic drug first introduced in the 1950s. It is suggested to have a low level of side effects (especially for movement disorders). Its use is regional and restricted to countries like Germany, Poland, the Netherlands and the former Yugoslavia. Perazine has being shown to be a potent inhibitor of human CYP1A2. It acts as a dopamine antagonist.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3356 |
|||
Target ID: CHEMBL217 |
|||
Target ID: Cytochrome P450 2B, Rattus norvegicus |
45.0 µM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Taxilan Approved UseTaxilan is used in the treatment of schizophrenia |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. | 2010-10-15 |
|
| [Perazine in the treatment of psychotic disorders--research review]. | 2010-08-03 |
|
| The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes. | 2010-03 |
|
| Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. | 2009-12 |
|
| Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. | 2009-09-16 |
|
| Validation of derivative spectrophotometry method for determination of active ingredients from neuroleptics in pharmaceutical preparations. | 2009-08-26 |
|
| Perazine elevates clozapine serum levels by inhibiting hepatic metabolism. | 2009-08-01 |
|
| Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism--an in vitro study. | 2009-07-23 |
|
| [Application of liquid chromatography coupled with mass spectrometry (LC/MS) to determine antidepressants in blood samples]. | 2009-05-16 |
|
| [Antipsychotics in clinical practice. Treatment of the first schizophrenic episode]. | 2009-05-16 |
|
| Spectroscopic and electrochemical analysis of psychotropic drugs. | 2009-01 |
|
| [Drug-induced agranulocytosis--case reports and literature review]. | 2009 |
|
| The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). | 2008-12-22 |
|
| Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. | 2008-06 |
|
| Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. | 2008-02 |
|
| Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE). | 2008 |
|
| The activity of cytochrome P450 CYP2B in rat liver during neuroleptic treatment. | 2007-08-26 |
|
| Simple and simultaneous determination for 12 phenothiazines in human serum by reversed-phase high-performance liquid chromatography. | 2007-07-01 |
|
| [Ischemic colitis without atherosclerosis?]. | 2007-03-30 |
|
| Perazine and carbamazepine in comparison to olanzapine in schizophrenia. | 2007 |
|
| Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. | 2006-10-20 |
|
| Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. | 2006-08 |
|
| [Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006-06 |
|
| Perazine for schizophrenia. | 2006-04-19 |
|
| Effect of chronic treatment with perazine on lipopolysaccharide-induced interleukin-1 beta levels in the rat brain. | 2006-04 |
|
| Analysis of phenothiazines in human body fluids using disk solid-phase extraction and liquid chromatography. | 2006-03-11 |
|
| Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. | 2006-03 |
|
| Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. | 2006-01-18 |
|
| Interactions between neuroleptics and CYP2C6 in rat liver--in vitro and ex vivo study. | 2005-09-14 |
|
| Direct effects of neuroleptics on the activity of CYP2A in the liver of rats. | 2005-09-14 |
|
| Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. | 2005-06 |
|
| Acute psychosis with a mediastinal carcinoma metastasis. | 2005-01 |
|
| Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms. | 2005-01 |
|
| Schizophrenia. | 2004-12 |
|
| Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. | 2004-08 |
|
| Halogenation of drugs enhances membrane binding and permeation. | 2004-05-03 |
|
| The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. | 2004-05 |
|
| Blood dyscrasias induced by psychotropic drugs. | 2004-03 |
|
| The AMUP study for drug surveillance in psychiatry - a summary of inpatient data. | 2004-03 |
|
| Schizophrenia. | 2003-12 |
|
| Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine. | 2003-05-08 |
|
| Effects of cytochrome P-450 inducers on the perazine metabolism in a primary culture of human hepatocytes. | 2003-04-24 |
|
| Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. | 2003-03 |
|
| Which neuroleptic would psychiatrists take for themselves or their relatives? | 2003-02 |
|
| Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. | 2003-02 |
|
| Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. | 2003-01-14 |
|
| The contribution of cytochrome P-450 isoenzymes to the metabolism of phenothiazine neuroleptics. | 2002-10 |
|
| An acute psychotic disorder caused by pefloxacin: a case report. | 1996-02 |
|
| [Electroconvulsive therapy in treatment of acute life threatening catatonia in toxic epidermal necrolysis (Lyell syndrome)]. | 1992-05 |
|
| Neurologic complications in patients treated with lithium. | 1988-09 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: In acutely ill and severely disturbed patients 50 mg perazine at time-intervals of 30 minutes can be administered intramuscularly
The customary dose range recommended for this antipsychotic under in-patient conditions is 75-600 mg/day (maximum 1000 mg/day).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:38:49 GMT 2025
by
admin
on
Mon Mar 31 18:38:49 GMT 2025
|
| Record UNII |
3VG1507988
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000079420
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
5282417
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
14516-56-4
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
SUB14812MIG
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY | |||
|
3VG1507988
Created by
admin on Mon Mar 31 18:38:49 GMT 2025 , Edited by admin on Mon Mar 31 18:38:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |